LifeMine taps fungal genomes for new drug candidates 

Led by Rick Klausner and Gregory Verdine, LifeMine has found drug candidates with novel mechanisms using its data science platform for mining fungal genomes.

The company now has an additional $50 million to move its first programs toward the clinic, raising the funds in a series B round announced on Jan. 7 and led by co-founder and Chairman Klausner and Milky Way Investments. On the same day, LifeMine Therapeutics Inc. announced William Kaelin, an awardee of the 2019 Nobel Prize in Physiology or Medicine, joined the board...